David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition
Biologist David Sinclair plans to test an oral reprogramming drug in a $101 million XPrize competition aimed at reversing biological age. This approach seeks to achieve systemic rejuvenation across the body, contrasting with localized gene therapies.
Why it matters
The competition represents a high-stakes effort to accelerate the development of accessible, whole-body anti-aging treatments.
The next step in the youth quest is a technology called chemical reprogramming.
The article provides a balanced overview of the scientific goals and the competitive landscape of longevity research.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in